$GYRE 4/A SEC Filings

Filed On	Filing
10 Jan 2025	Form 4/A: Ma Songjiang, Director Sold 833 shares ($9.87K)
26 Apr 2021	Form 4/A: Usman Nassim, Director Granted 140,000 Stock Option (Right to Buy)
26 Apr 2021	Form 4/A: Musil Clinton, Chief Financial Officer Granted 54,000 Stock Option (Right to Buy)
26 Apr 2021	Form 4/A: Levy Howard, Chief Medical Officer Granted 25,000 Stock Option (Right to Buy)
14 Feb 2019	Form 4/A: Levy Howard, Chief Medical Officer Holds 11,694 shares of Common Stock
21 Mar 2018	Form 4/A: Flynn James E, 10% owner and 4 others Sold 52,461 shares ($1.62M) · Sold 10,000 shares ($300K) · Sold 9,317 shares ($272K)
13 Jun 2016	Form 4/A: Usman Nassim, Director Acquired 0 Stock Option (Right to Buy) (Other Transaction)
15 Dec 2015	Form 4/A: Usman Nassim, Director Granted 153,572 Stock Option (Right to Buy)
15 Dec 2015	Form 4/A: Selick Harold E, Director Granted 6,750 Stock Option (Right to Buy)
15 Dec 2015	Form 4/A: Richard John P, Director Granted 6,750 Stock Option (Right to Buy)
15 Dec 2015	Form 4/A: Payne Fletcher, Chief Financial Officer Granted 28,572 Stock Option (Right to Buy)
15 Dec 2015	Form 4/A: Madison Edwin, Chief Scientific Officer Granted 58,572 Stock Option (Right to Buy)
15 Dec 2015	Form 4/A: Lawlor Augustine, Director Granted 6,750 Stock Option (Right to Buy)
15 Dec 2015	Form 4/A: Hill Stephen A, Director Granted 6,750 Stock Option (Right to Buy)
15 Dec 2015	Form 4/A: Desouza Errol B, Director Granted 6,750 Stock Option (Right to Buy)
17 Jan 2014	Form 4/A: Richard John P, Director Disposed of 10,000 Common Stock, $0.001 par value per share (Grant/Award Acquisition)
11 Mar 2013	Form 4/A: Hill Stephen A, Director Bought 10,000 shares ($44.8K) · Bought 10,000 shares ($43.8K)
20 Nov 2012	Form 4/A: Bvf Partners L P/IL, 10% owner and 5 others Bought 595,000 shares ($2.38M)
13 May 2011	Form 4/A: Burrill Steven, Director Received 16,948 shares by exercise or conversion ($159K) · Sold 18,948 shares ($456K) · Received 33,052 shares by exercise or conversion ($242K) · 1 more
02 Mar 2011	Form 4/A: Caldwell William S, SVP - Drug Discovery and Dev. Exercised 22,015 Stock Option (Right to Buy)

Comments